These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

201 related articles for article (PubMed ID: 10205793)

  • 1. Human antibodies to the 19kDa C-terminal fragment of Plasmodium falciparum merozoite surface protein 1 inhibit parasite growth in vitro.
    Egan AF; Burghaus P; Druilhe P; Holder AA; Riley EM
    Parasite Immunol; 1999 Mar; 21(3):133-9. PubMed ID: 10205793
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Immunogenicity of a chimeric Plasmodium falciparum merozoite surface protein vaccine in Aotus monkeys.
    Burns JM; Miura K; Sullivan J; Long CA; Barnwell JW
    Malar J; 2016 Mar; 15():159. PubMed ID: 26975721
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Serum antibodies from malaria-exposed people recognize conserved epitopes formed by the two epidermal growth factor motifs of MSP1(19), the carboxy-terminal fragment of the major merozoite surface protein of Plasmodium falciparum.
    Egan AF; Chappel JA; Burghaus PA; Morris JS; McBride JS; Holder AA; Kaslow DC; Riley EM
    Infect Immun; 1995 Feb; 63(2):456-66. PubMed ID: 7822010
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Growth-inhibitory antibodies are not necessary for protective immunity to malaria infection.
    Murhandarwati EE; Wang L; de Silva HD; Ma C; Plebanski M; Black CG; Coppel RL
    Infect Immun; 2010 Feb; 78(2):680-7. PubMed ID: 19917716
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Malaria parasite-inhibitory antibody epitopes on Plasmodium falciparum merozoite surface protein-1(19) mapped by TROSY NMR.
    Morgan WD; Lock MJ; Frenkiel TA; Grainger M; Holder AA
    Mol Biochem Parasitol; 2004 Nov; 138(1):29-36. PubMed ID: 15500913
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Results from tandem Phase 1 studies evaluating the safety, reactogenicity and immunogenicity of the vaccine candidate antigen Plasmodium falciparum FVO merozoite surface protein-1 (MSP1(42)) administered intramuscularly with adjuvant system AS01.
    Otsyula N; Angov E; Bergmann-Leitner E; Koech M; Khan F; Bennett J; Otieno L; Cummings J; Andagalu B; Tosh D; Waitumbi J; Richie N; Shi M; Miller L; Otieno W; Otieno GA; Ware L; House B; Godeaux O; Dubois MC; Ogutu B; Ballou WR; Soisson L; Diggs C; Cohen J; Polhemus M; Heppner DG; Ockenhouse CF; Spring MD
    Malar J; 2013 Jan; 12():29. PubMed ID: 23342996
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Immunity to recombinant plasmodium falciparum merozoite surface protein 1 (MSP1): protection in Aotus nancymai monkeys strongly correlates with anti-MSP1 antibody titer and in vitro parasite-inhibitory activity.
    Singh S; Miura K; Zhou H; Muratova O; Keegan B; Miles A; Martin LB; Saul AJ; Miller LH; Long CA
    Infect Immun; 2006 Aug; 74(8):4573-80. PubMed ID: 16861644
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Crystal structure of a Fab complex formed with PfMSP1-19, the C-terminal fragment of merozoite surface protein 1 from Plasmodium falciparum: a malaria vaccine candidate.
    Pizarro JC; Chitarra V; Verger D; Holm I; Pêtres S; Dartevelle S; Nato F; Longacre S; Bentley GA
    J Mol Biol; 2003 May; 328(5):1091-103. PubMed ID: 12729744
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A chimeric Plasmodium falciparum merozoite surface protein vaccine induces high titers of parasite growth inhibitory antibodies.
    Alaro JR; Partridge A; Miura K; Diouf A; Lopez AM; Angov E; Long CA; Burns JM
    Infect Immun; 2013 Oct; 81(10):3843-54. PubMed ID: 23897613
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Merozoite Surface Protein 1 from Plasmodium falciparum Is a Major Target of Opsonizing Antibodies in Individuals with Acquired Immunity against Malaria.
    Jäschke A; Coulibaly B; Remarque EJ; Bujard H; Epp C
    Clin Vaccine Immunol; 2017 Nov; 24(11):. PubMed ID: 28877929
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Epitopes in the 19kDa fragment of the Plasmodium falciparum major merozoite surface protein-1 (PfMSP-1(19)) recognized by human antibodies.
    Shai S; Blackman MJ; Holder AA
    Parasite Immunol; 1995 May; 17(5):269-75. PubMed ID: 7545808
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The Plasmodium falciparum merozoite surface protein-1 19 KD antibody response in the Peruvian Amazon predominantly targets the non-allele specific, shared sites of this antigen.
    Sutton PL; Clark EH; Silva C; Branch OH
    Malar J; 2010 Jan; 9():3. PubMed ID: 20047674
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The antibody response to Plasmodium falciparum Merozoite Surface Protein 4: comparative assessment of specificity and growth inhibitory antibody activity to infection-acquired and immunization-induced epitopes.
    de Silva HD; Saleh S; Kovacevic S; Wang L; Black CG; Plebanski M; Coppel RL
    Malar J; 2011 Sep; 10():266. PubMed ID: 21920045
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Dominance of conserved B-cell epitopes of the Plasmodium falciparum merozoite surface protein, MSP1, in blood-stage infections of naive Aotus monkeys.
    Hui GS; Nikaido C; Hashiro C; Kaslow DC; Collins WE
    Infect Immun; 1996 May; 64(5):1502-9. PubMed ID: 8613353
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Fine specificity of anti-MSP119 antibodies and multiplicity of Plasmodium falciparum merozoite surface protein 1 types in individuals in Nigeria with sub-microscopic infection.
    Ngoundou-Landji J; Nwuba RI; Anumudu CI; Odaibo AB; Matondo Maya WD; Awobode HO; Okafor CM; Morenikeji OA; Asinobi A; Nwagwu M; Holder AA; Ntoumi F
    Malar J; 2010 Oct; 9():287. PubMed ID: 20955565
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Analysis of antibodies directed against merozoite surface protein 1 of the human malaria parasite Plasmodium falciparum.
    Woehlbier U; Epp C; Kauth CW; Lutz R; Long CA; Coulibaly B; Kouyaté B; Arevalo-Herrera M; Herrera S; Bujard H
    Infect Immun; 2006 Feb; 74(2):1313-22. PubMed ID: 16428781
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Identification of a novel antigenic domain of Plasmodium falciparum merozoite surface protein-1 that specifically binds to human erythrocytes and inhibits parasite invasion, in vitro.
    Nikodem D; Davidson E
    Mol Biochem Parasitol; 2000 Apr; 108(1):79-91. PubMed ID: 10802320
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Naturally acquired human antibodies which recognize the first epidermal growth factor-like module in the Plasmodium falciparum merozoite surface protein 1 do not inhibit parasite growth in vitro.
    Chappel JA; Egan AF; Riley EM; Druilhe P; Holder AA
    Infect Immun; 1994 Oct; 62(10):4488-94. PubMed ID: 7927713
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A malaria vaccine based on the polymorphic block 2 region of MSP-1 that elicits a broad serotype-spanning immune response.
    Cowan GJ; Creasey AM; Dhanasarnsombut K; Thomas AW; Remarque EJ; Cavanagh DR
    PLoS One; 2011; 6(10):e26616. PubMed ID: 22073118
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Antibodies against merozoite surface protein (MSP)-1(19) are a major component of the invasion-inhibitory response in individuals immune to malaria.
    O'Donnell RA; de Koning-Ward TF; Burt RA; Bockarie M; Reeder JC; Cowman AF; Crabb BS
    J Exp Med; 2001 Jun; 193(12):1403-12. PubMed ID: 11413195
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.